Claudia Fox, ENDO 2021: Exenatide for Weight Loss Maintenance in Adolescents
We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity.
‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What are the major challenges to weight loss maintenance among adolescents with severe obesity? (0:25)
- What is the rationale for the use of exenatide in non-diabetic obese adolescents? (2:26)
- Could you tell us a little about the aims, design and inclusion criteria of your study? (4:08)
- What were the efficacy and safety findings of the study? (5:39)
- What are the implications of these findings for the routine use of exenatide for weight loss maintenance among adolescents with severe obesity, and what questions remain unanswered? (7:52)
Disclosures: Claudia Fox discloses receiving research support from Novo Nordisk and Rhythm Pharmaceuticals.
Support:Â Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
